Irvin M. Modlin

Yale University — United States

Medicine · Health Sciences

81h-index28.1kcitations551works2.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroendocrine Tumor Research Advances(257), Lung Cancer Research Studies(153), Neuroblastoma Research and Treatments(139), Helicobacter pylori-related gastroenterology studies(58), Neuropeptides and Animal Physiology(56)

Publications546 total

A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS).
Journal of Clinical Oncology·2025
The central role of gastrin in <i>Helicobacter pylori</i> gastric carcinogenesis
Scandinavian Journal of Gastroenterology·2025· 1 citedOpen Access
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)
Journal of Nuclear Medicine·2025· 1 citedOpen Access
Trends in the Management and Outcomes of Neuroendocrine Liver Metastases
Annals of Surgery·2024· 1 cited
Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood
The Prostate·2024· 12 citedOpen Access
The Historical Evolution of Neuroendocrine Tumor Disease
2024· 1 cited
Evaluation of a Multigenomic Liquid Biopsy (PROSTest) for Prostate Cancer Detection and Follow-Up in a Caribbean Population
SSRN Electronic Journal·2024Open Access
Development and validation of a multigenomic liquid biopsy (PROSTest) for prostate cancer detection.
Journal of Clinical Oncology·2023· 2 cited
Prediction of early prostate cancer recurrence using a liquid biopsy approach.
Journal of Clinical Oncology·2023· 2 cited
Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for <sup>177</sup>Lu-PSMA therapy in advanced prostate cancer.
Journal of Clinical Oncology·2023· 2 cited
Neuroendocrine Tumors: Therapy with Radiolabeled Peptides
2022· 1 cited
Clinical and scientific considerations of genomics and metabolomics in radionuclide therapy
Nuclear Medicine and Molecular Imaging·2022
Neuroendocrine Tumors: Therapy with Radiolabeled Peptides
2022
Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors
2022
Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors
2022· 1 cited
Neuroendocrine Tumors: Therapy with Radiolabeled Peptides
2022
A Sensitive, Portable Microfluidic Device for SARS-CoV-2 Detection from Self-Collected Saliva
Infectious Disease Reports·2021· 15 citedOpen Access
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy
Endocrine Related Cancer·2021· 13 citedOpen Access
A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility
Annals of Oncology·2021· 46 citedOpen Access
Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy
Annals of Surgery·2021· 32 citedOpen Access
page 1 of 28Next →

Frequent Co-authors

Mark Kidd(30), Björn Gustafsson(9), Ignat Drozdov(7), Steven F. Moss(5), Igor Latich(5), Anthony Chan(5), Lisa Bodei(5), Michelle N. Zikusoka(4), Michael D. Shapiro(4), Andrea Frilling(4), Dik J. Kwekkeboom(4), Geeta N. Eick(4), Kevin D. Lye(3), Eric P. Krenning(3), András Sándor(3), Bernhard Svejda(3), Laura H. Tang(3), Øyvind Hauso(3), Garth H. Ballantyne(3), Kjell Öberg(2)